Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report
Journal of Immunotherapy and Precision Oncology · 24.08.2026 · 9 (4) · 124-129
DOI: 10.36401/jipo-25-32 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Immunotherapy and Precision Oncology, erschienen am 24.08.2026. Verfasst von Marina Crespo-Cruz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London, UK. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immunotherapy is an established treatment for mismatch repair–deficient (dMMR) colorectal cancer (CRC), driven by increased neoantigen formation and enhanced responsiveness to immune checkpoint inhibitors. Nous-209 is a polyvalent viral vector immunotherapy under investigation in combination with pembrolizumab in the NOUS-209-01 clinical trial (ClinicalTrials.gov Identifier: NCT04041310) in patients with dMMR CRC. Here, we report on a participant of the NOUS-209-01 trial who achieved a complete pathologic response and significant regression of colonic polyps following treatment with Nous-209 in combination with pembrolizumab and a right hemicolectomy. Genetic testing ruled out Lynch syndrome and mosaicism of Lynch syndrome–associated genes. The patient remains relapse free and under active surveillance 18 months after treatment initiation. Three months after treatment ended, the patient experienced an episode of grade 3 immune-mediated colitis and this improved after infliximab treatment. The clinical and immunologic findings suggest the potential for Nous-209 immunotherapy, in combination with pembrolizumab, to induce regression of both malignant and premalignant colonic lesions. To our knowledge, this is the first report of an immunotherapy combination to reduce premalignant polyps in a patient who does not have Lynch syndrome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
- Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, UK.
- Department of Endoscopy, St Mark's the National Bowel Hospital and Academic Institute, London, UK.
- Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
- Department of Colorectal Surgery, St Mark's the National Bowel Hospital and Academic Institute, London, UK.
- Department of Gastroenterology, St Mark's the National Bowel Hospital and Academic Institute, London, UK.
ORCID-Profile: Marina Crespo-Cruz
Zitieren
APA
Crespo-Cruz, M., Rodriguez-Justo, M., Humphries, A., Plumb, A., Antoniou, A., Monahan, K., Runswick, S., Capone, A., Antonucci, L., Garzia, I., Micarelli, E., Scarselli, E., D'Alise, A. M., Gogov, S., & Shiu, K. K. (2026). Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report. Journal of Immunotherapy and Precision Oncology, 9(4), 124-129. https://doi.org/10.36401/jipo-25-32
Vancouver
Crespo-Cruz M, Rodriguez-Justo M, Humphries A, Plumb A, Antoniou A, Monahan K, et al. Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report. Journal of Immunotherapy and Precision Oncology. 2026;9(4):124-129. doi:10.36401/jipo-25-32
BibTeX
@article{CrespoCruz2026,
author = {Crespo-Cruz, Marina and Rodriguez-Justo, Manuel and Humphries, Adam and Plumb, Andrew and Antoniou, Anthony and Monahan, Kevin and Runswick, Sarah and Capone, Alessia and Antonucci, Laura and Garzia, Irene and Micarelli, Elisa and Scarselli, Elisa and D'Alise, Anna Morena and Gogov, Sven and Shiu, Kai-Keen},
title = {Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report},
journal = {Journal of Immunotherapy and Precision Oncology},
year = {2026},
volume = {9},
number = {4},
pages = {124--129},
doi = {10.36401/jipo-25-32}
}
EUVIMED